Towards evidence-based pharmacotherapy in children

Paediatric Anaesthesia

Volumn 21, Issue 3, 2011, Pages 183-189

  Kemper, Elles Marleen ^a   Merkus, Maruschka ^a   Wierenga, Peter C ^a   Van Rijn, Petra C ^a   Van Der Werff, Desirée ^b   Lie A Huen, Loraine ^a   Offringa, Martin ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

children; clinical trials; evidence based; pharmacotherapy; regulation

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BENZYL ALCOHOL; CYTOCHROME P450; GLYCOL; MIDAZOLAM; NEUROLEPTIC AGENT; PARACETAMOL; PROPYLENE;

ADVERSE DRUG REACTION; AGITATION; BRAIN HEMORRHAGE; CHILD; DRUG ADMINISTRATION ROUTE; DRUG DOSE; DRUG FORMULATION; DRUG LEGISLATION; DRUG THERAPY; EVIDENCE BASED MEDICINE; EXCITEMENT; HUMAN; KERNICTERUS; OFF LABEL DRUG USE; PARADOXICAL DRUG REACTION; PEDIATRICS; PRESCRIPTION; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SIDE EFFECT;

ACADEMIES AND INSTITUTES; ADULT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INDUSTRY; DRUG THERAPY; EUROPEAN UNION; EVIDENCE-BASED MEDICINE; HUMANS; LEGISLATION, DRUG; OFF-LABEL USE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 79951610193     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2010.03493.x     Document Type: Review

References (53)

1. Caldwell PH, Murphy SB, Butow PN, et al. Clinical trials in children. Lancet 2004; 364: 803-811. (Pubitemid 39165102)
2. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000; 320: 79-82. (Pubitemid 30173044)
3. 't JongGW, Vulto AG, de Hoog M, et al. Unapproved and off-label use of drugs in a children's hospital. N Engl J Med 2000; 343: 1125.
4. Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003; 290: 905-911. (Pubitemid 37430462)
5. Cote CJ, Alexander J,. Drug development for children: the past, the present, hope for the future. Paediatr Anaesth 2003; 13: 279-283. (Pubitemid 36629641)
6. Weiss CF, Glazko AJ, Weston JK,. Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med 1960; 262: 787-794.
7. Garson A Jr,. Medicolegal problems in the management of cardiac arrhythmias in children. Pediatrics 1987; 79: 84-88. (Pubitemid 17060961)
8. McFarlan CS, Anderson BJ, Short TG,. The use of propofol infusions in paediatric anaesthesia: a practical guide. Paediatr Anaesth 1999; 9: 209-216. (Pubitemid 29220117)
9. Engelhardt T, McCheyne AJ, Morton N, et al. Clinical adaptation of a pharmacokinetic model of Propofol plasma concentrations in children. Paediatr Anaesth 2008; 18: 235-239. (Pubitemid 351159907)
10. Cohen E, Uleryk E, Jasuja M, et al. An absence of pediatric randomized controlled trials in general medical journals, 1985-2004. J Clin Epidemiol 2007; 60: 118-123. (Pubitemid 46039874)
11. Bellu R, de Waal KA, Zanini R, Opioids for neonates receiving mechanical ventilation. Cochrane Database Syst Rev 2008: CD004212.
12. Fredriksson A, Archer T, Alm H, et al. Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration. Behav Brain Res 2004; 153: 367-376. (Pubitemid 38953110)
13. Wang C, Sadovova N, Fu X, et al. The role of the N-methyl-D-aspartate receptor in ketamine-induced apoptosis in rat forebrain culture. Neuroscience 2005; 132: 967-977. (Pubitemid 40602532)
14. Soriano SG, Anand KJ, Rovnaghi CR, et al. Of mice and men: should we extrapolate rodent experimental data to the care of human neonates? Anesthesiology 2005; 102: 866-868.
15. Anand KJ, Soriano SG,. Anesthetic agents and the immature brain: are these toxic or therapeutic? Anesthesiology 2004; 101: 527-530. (Pubitemid 38988508)
16. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics 2002; 110 (1 Pt 1): 181-183.
17. Cramer K, Wiebe N, Moyer V, et al. Children in reviews: methodological issues in child-relevant evidence syntheses. BMC Pediatr 2005; 5: 38.
18. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167. (Pubitemid 37122329)
19. DeWoskin RS, Thompson CM,. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol 2008; 51: 66-86.
20. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76.
21. Fisher DM, O'Keeffe C, Stanski DR, et al. Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. Anesthesiology 1982; 57: 203-208. (Pubitemid 12057041)
22. Johnson TN,. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 2003; 192: 37-48. (Pubitemid 37153342)
23. Santeiro ML, Christie J, Stromquist C, et al. Pharmacokinetics of continuous infusion fentanyl in newborns. J Perinatol 1997; 17: 135-139. (Pubitemid 127453392)
24. Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008; 101: 680-689.
25. Bouwmeester NJ, Anderson BJ, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 2004; 92: 208-217. (Pubitemid 38159658)
26. Massanari M, Novitsky J, Reinstein LJ,. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr (Phila) 1997; 36: 681-684. (Pubitemid 27527875)
27. Lerman J, Robinson S, Willis MM, et al. Anesthetic requirements for halothane in young children 0-1 month and 1-6 months of age. Anesthesiology 1983; 59: 421-424. (Pubitemid 14227515)
28. LeDez KM, Lerman J,. The minimum alveolar concentration (MAC) of isoflurane in preterm neonates. Anesthesiology 1987; 67: 301-307. (Pubitemid 18077407)
29. Taylor RH, Lerman J,. Minimum alveolar concentration of desflurane and hemodynamic responses in neonates, infants, and children. Anesthesiology 1991; 75: 975-979.
30. Menson EN, Walker AS, Sharland M, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006; 332: 1183-1187.
31. (Britisch National Formulary for Children), (at October 20th 2010).
32. (Dutch children's formulary), (at October 20th 2010).
33. Allegaert K, Anderson BJ, Vrancken M, et al. Impact of a paediatric vial on the magnitude of systematic medication errors in neonates. Paediatr Perinat Drug Ther 2006; 7: 59-63. (Pubitemid 44299033)
34. Allegaert K, Murat I, Anderson BJ,. Not all intravenous paracetamol formulations are created equal. Paediatr Anaesth 2007; 17: 811-812. (Pubitemid 47000660)
35. Schirm E, Tobi H, de Vries TW, et al. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr 2003; 92: 1486-1489. (Pubitemid 38114502)
36. Pawar S, Kumar A,. Issues in the formulation of drugs for oral use in children: role of excipients. Paediatr Drugs 2002; 4: 371-379. (Pubitemid 34651926)
37. Hiller JL, Benda GI, Rahatzad M, et al. Benzyl alcohol toxicity: impact on mortality and intraventricular hemorrhage among very low birth weight infants. Pediatrics 1986; 77: 500-506. (Pubitemid 16104462)
38. Arulanantham K, Genel M,. Central nervous system toxicity associated with ingestion of propylene glycol. J Pediatr 1978; 93: 515-516. (Pubitemid 8384118)
39. Standing JF, Khaki ZF, Wong IC,. Poor formulation information in published pediatric drug trials. Pediatrics 2005; 116: e559-e562. (Pubitemid 44542798)
40. Radley DC, Finkelstein SN, Stafford RS,. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021-1026.
41. Stafford RS,. Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med 2008; 358: 1427-1429. (Pubitemid 351482734)
42. Gill AM, Leach HJ, Hughes J, et al. Adverse drug reactions in a paediatric intensive care unit. Acta Paediatr 1995; 84: 438-441.
43. Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88: 965-968. (Pubitemid 29448261)
44. Horen B, Montastruc JL, Lapeyre-Mestre M,. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54: 665-670. (Pubitemid 36002596)
45. Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004; 27: 1059-1067. (Pubitemid 39487067)
46. Schirm E, Tobi H, van Puijenbroek EP, et al. Reported adverse drug reactions and their determinants in Dutch children outside the hospital. Pharmacoepidemiol Drug Saf 2004; 13: 159-165. (Pubitemid 38332049)
47. Sammons HM, Gray C, Hudson H, et al. Safety in paediatric clinical trials-a 7-year review. Acta Paediatr 2008; 97: 474-477. (Pubitemid 351432298)
48. Steinbrook R,. Testing medications in children. N Engl J Med 2002; 347: 1462-1470. (Pubitemid 35239728)
49. Bosch X,. Pediatric medicine. Europe follows U.S. in testing drugs for children. Science 2005; 309: 1799. (Pubitemid 41325059)
50. Benjamin DK Jr, Smith PB, Murphy MD, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 2006; 296: 1266-1273. (Pubitemid 44394898)
51. Boots I, Sukhai RN, Klein RH, et al. Stimulation programs for pediatric drug research-do children really benefit? Eur J Pediatr 2007; 166: 849-855. (Pubitemid 46988181)
52. Davidson AJ, O'Brien M,. Ethics and medical research in children. Paediatr Anaesth 2009; 19: 994-1004.
53. Waisel DB,. Moral responsibility to attain thorough pediatric drug labeling. Paediatr Anaesth 2009; 19: 989-993.